- Home
- SFWL vs STTK Comparison
SFWL vs STTK Comparison
Compare SFWL & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- STTK
- Stock Information
- Founded
- SFWL 2001
- STTK 2016
- Country
- SFWL China
- STTK United States
- Employees
- SFWL N/A
- STTK N/A
- Industry
- SFWL Trucking Freight/Courier Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- STTK Health Care
- Exchange
- SFWL Nasdaq
- STTK Nasdaq
- Market Cap
- SFWL 82.3M
- STTK 83.8M
- IPO Year
- SFWL 2023
- STTK 2020
- Fundamental
- Price
- SFWL $1.15
- STTK $1.92
- Analyst Decision
- SFWL
- STTK Hold
- Analyst Count
- SFWL 0
- STTK 6
- Target Price
- SFWL N/A
- STTK $2.67
- AVG Volume (30 Days)
- SFWL 24.3K
- STTK 1.6M
- Earning Date
- SFWL 08-27-2025
- STTK 11-13-2025
- Dividend Yield
- SFWL N/A
- STTK N/A
- EPS Growth
- SFWL 31.68
- STTK N/A
- EPS
- SFWL 0.14
- STTK N/A
- Revenue
- SFWL $540,461,000.00
- STTK $2,997,000.00
- Revenue This Year
- SFWL N/A
- STTK N/A
- Revenue Next Year
- SFWL N/A
- STTK N/A
- P/E Ratio
- SFWL $8.11
- STTK N/A
- Revenue Growth
- SFWL 21.10
- STTK N/A
- 52 Week Low
- SFWL $0.86
- STTK $0.69
- 52 Week High
- SFWL $1.60
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- SFWL 57.68
- STTK 72.13
- Support Level
- SFWL $1.10
- STTK $1.68
- Resistance Level
- SFWL $1.18
- STTK $2.04
- Average True Range (ATR)
- SFWL 0.09
- STTK 0.19
- MACD
- SFWL 0.01
- STTK 0.09
- Stochastic Oscillator
- SFWL 51.72
- STTK 89.29
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.